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Direct in vivo assessment of parathyroid hormone-calcium relation
curve in renal patients. Secondary hyperparathyroidism (SHP) is a well
documented finding even in the early stages of chronic renal failure
(CRF). A sigmoidal relationship, fitting a four parameter model, links
PTH secretion rate and calcium concentration changes. To our knowl-
edge, PTH secretory parameters have only been studied in uremic patients
who are in dialysis treatment. As a result of these studies, a possible role
for derangement in setpoint values (that is, the serum calcium concentra-
tion corresponding to the mid-range value on the sigmoidal curve) has
been suggested in the pathogenesis of SHP in CRF. Our study was
undertaken to gain insight into the calcium-PTH relationship curve in the
first course of CRF and to assess whether a change in any of the secretory
parameters is related to the beginning of SHP. We studied 27 male renal
patients with a variable degree of renal function (creatinine clearance 12
to 164 mI/mm) and 9 control subjects. In all patients and controls the
following parameters were evaluated: (1) basal 1,25(OH)2 vitamin D,
25(OH)vitamin D, calcitonin (CT), intact PTH; (2) GFR by Cr51EDTA
clearance; (3) the sigmoidal PTH-ionized calcium relation curve, by means
of a hypocalcemic stimulating test (Na2-EDTA 37mg/kg body weight/2 hr)
and a hypercalcemic test (Ca gluconate giving 8 mg/kg of body weight/2 hr
of Ca element), performed on two consecutive days. The main results
were: (1) the progressive reduction of GFR was accompanied by an
increase in the maximum secretory capacity of PTH, without any change
in setpoint values; (2) in addition to the already known factors, CT seems
to be, in some as yet undefined way, related to PTH hypersecretion in the
course of CRF.
Increased parathyroid hormone (PTh) secretion develops early
in the course of chronic renal failure (CRF) [1, 2], owing to
multiple pathogenetic factors, with a major role played by phos-
phate retention, reduced availability of calcitriol and/or of its
parathyroid gland receptors, and skeletal resistance to the calce-
mic action of PTH [3—18].
It is also known, by in vivo and in vitro studies, that PTH
secretion varies as a function of serum calcium concentration in a
curvilinear fashion that resembles a sigmoidal curve [19—22],
characterized by four main parameters: maximal PTH (PTHm,)
which represents the maximum stimulated PTH levels; minimal
PTH (PTHmin) representing maximum PTH inhibition; the slope
of the curve in the straight part, which provides information on
the sensitivity of the parathyroid glands; and the setpoint, that is
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the calcium concentration corresponding to half-maximal inhibi-
tion of PTH (that is, the midrange value).
Brown et al [20, 21] demonstrated in in vitro studies that the
calcium-PTH relation curve was shifted to the right in parathyroid
glands obtained from patients with both primary and secondary
hyperparathyroidism. Several authors have also examined PTH
secretion kinetics in patients with CRF [23—27]. Felsenfeld et al
[26] reported different patterns of calcium-mediated PTH secre-
tion among patients with different types of renal osteodystrophy.
Delmez et al [24] and Dunlay et al [25] demonstrated that vitamin
D administration in dialyzed patients induced a marked suppres-
sion of PTH levels, together with a shift of the sigmoidal
calcium-PTH curve to the left and downward. From these studies,
it could be supposed that changes in the PTH secretory parame-
ters, dependent or not on vitamin D deficiency, might play a
causative role in secondary hyperparathyroidism (SHP) in CRF.
On the other hand, more recently, Ramirez et al [27] were not
able to find any change in the setpoint values of uremic patients.
However, all the above studies were performed with uremic
patients in dialysis treatment. Furthermore, the methodology for
the assessment of the secretory parameters was quite different in
the various studies, preventing the possibility of a direct compar-
ison of the results.
To our knowledge, no information is yet available on PTH
secretion kinetics during the development of renal failure.
The current study was undertaken to investigate calcium-
mediated PTH secretion in the early course of CRF and, secondly,
to assess whether the beginning of SHP is in some way related to
changes in any of the PTH secretory parameters.
Methods
Patients
The study was performed on 27 male patients, aged 20 to 72
years, who were suffering from biopsy-proven glomerulonephritis
(16 patients), renal vascular disease with hypertension (4 pa-
tients), chronic interstitial nephritis (7 patients), Alport's disease
(1 patient), and 9 normal male subjects, aged 28 to 54 years.
The patients' renal function was substantially stable in the six
months prior to the study, ranging from 12 to 164 ml/min of
creatinine clearance; their urinary protein excretion was under 3.5
g/day.
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The four hypertensive patients had clonidine as an anti-hyper-
tensive drug. None of them received vitamin D compounds, oral
phosphate binders or diuretics for at least one month preceding
the study. The protein and phosphate content of the diet was not
restricted in patients with creatinine clearance above 35 mI/mm,
but was reduced to 0.6/kg body weight of proteins and 800 mg of
phosphate, plus 1000 mg of supplemented calcium, in the other
patients.
The study was carried out from October to March, the least
sunny months in our country. Before performing the study,
informed consent was obtained from each patient.
The study consisted of a basal evaluation of serum chemistry,
creatinine clearance, and 24 hr electrolytes (at least 2 consecutive
samples). On the last day of basal evaluation, the following
parameters were also evaluated: intact PTH, 1,25(OH)2 vitamin
D, 25(OH) vitamin D, calcitonin (Cl').
The following day (first study day), GFR was measured by
Cr51-EDTA clearance in each patient. Briefly, 1 MBq C51-EDTA
(Sorin Biomedica, Saluggia, Italy) was injected i.v. in a peripheral
vein of the arm in one minute; thereafter blood samples were
collected at 120, 180, 240 and 360 minutes from the peripheral
vein of the controlateral arm. Calculation of GFR was performed
according to Sapirstein et al [28].
On the second day, a hypocalcemic test was performed by
Na2-EDTA i.v. infusion. Briefly, Na2-EDTA was added to 5%
dextrose solution, in such an amount that about 37 mg/kg of body
wt were infused in 120 minutes, at a constant rate of 4.2 mI/mm of
solution, through an indwelling needle. Twenty milliliters of 1%
lidocaine were added in the flask to avoid local pain. Blood
samples were taken from the controlateral arm at times 0, 5, 10,
15, 30, 45, 75, 105, and 120 minutes to evaluate ionized calcium
and intact PTH; CT was also measured in the 0 and 120 minute
blood sample.
On the third study day, an infusion test with calcium gluconate
(calcium element 8 mg/kg of body wt in 2 hr) was performed; a
blood sample was obtained at times 0, 15, 30, 60, 90, and 120
minutes to evaluate ionized calcium and intact PTH. The basal
calcium concentrations on the day of calcium infusion substan-
tially overlapped the ones preceding the hypocalcemic test (1.26
0.05 vs. 1.25 0.05, P = NS).
Vital signs were monitored every 15 minutes during and for one
hour after both infusion tests.
Calculations of the PTH secretory parameters were performed
as follows. The maximal stimulated PTH (PTHm,) was the
maximal reached PTH value during Na2-EDTA infusion; this
value was reached in all patients between 45 and 75 minutes, and
then PTH values remained stable or decreased. The maximal
inhibited PTh (PTHmIn) was the lowest PTH obtained during i.v.
Ca infusion test; this value was reached between 30 and 60
minutes, and thereafter PTH levels remained substantially un-
changed. Sensitivity (Sens) was calculated from the slope of the
linear part of the sigmoidal curve described by the relationship
between the percentage of PTHm values of PTH and the
corresponding ionized calcium levels. The setpoint was calculated
as the ionized calcium value corresponding to the mid percentage
PTH value between PTHm and PTHmin, on the linear part of the
sigmoidal curve.
To test the validity of the above calculation, the obtained
secretory parameter values were entered in the formula defining
the theoretical sigmoidal curve according to Rodbard and Hutt
[29] (Appendix). The calculated and observed values of PTH were
then compared by linear regression: the r value was 0.961 (P <
0.000 1), with an intercepta value of 0.06 (not different from 0) and
the slope value of 0.97 (close to unity). Furthermore, the setpoint
value obtained by our method was compared with that obtained
by the logit/log curve (see Appendix for calculation) by linear
correlation analysis. The correlation coefficient was 0.921 (P <
0.0001), with "b" values very close to unity (0.96) and intercepta
not different from 0 (0.004).
The glomerular filtration rate (GFR), calculated as described
above, was expressed as corrected values for body surface area.
According to the GFR values, the renal patients (RP) were
divided into three groups: group RP1 (GFR >70 mI/mm; N 6),
group RP2 (GFR between 30 and 70 mI/mm; N = 13), group RP3
(GFR <30 mI/mm; N 8).
The nine control subjects (group C) were submitted to the same
study protocol, with the exception of GFR assessment by CrM
EDTA. Their GFR was indirectly evaluated by creatinine clear-
ance (ranging from 90 to 158 ml/min).
Electrolytes, creatinine and urea in serum and urine were
measured by standard methodology (autoanalyzer, absorption
spectrophotometry and flame photometry).
Serum ionized calcium was evaluated using an ICA 1 ionized
calcium analyzer (Radiometer, Copenhagen, Denmark).
PTH was measured by intact-PTH immunoradiometric assay
(IRMA, Nichols Institute Diagnostics, California, USA), utilizing
two different polyclonal antibodies, purified by affinity chroma-
tography, specific for 39-84 and 1-34 regions (normal values 7 to
55 pg/ml).The intra-assay coefficient of variation was 2.4% and the
interassay coefficient 5.7%.
Calcitonin (CT) was analyzed by radioimmunoassay with dou-
ble antibodies, in liquid phase (Nichols). This assay has been
proven to be specific for monomeric CT (the active hormone) and
has very low limits of detection (3 pg/ml) [30]. The intra-assay
coefficient of variation was 3.3% and the interassay coefficient
5.5%, with the normal range for males 4 to 20 pg/ml.
For vitamin D metabolite determination, a 10 ml blood sample
was collected with heparin, immediately centrifuged at 4°C and
stored at —20°C, until the assay was performed (not later than 20
days). Plasma 25(OH)D was measured after alcoholic extraction
by competitive protein binding assay for vitamin D binding
protein and tritiated antigen (Nichols). The intra-assay coefficient
of variation was 7.1% and the interassay coefficient 12.8% (nor-
mal range 16 to 74 ng/ml). For the 1,25(OH)2D assay, after
acetonitrile extraction in the presence of tritiated calcitriol as an
indicator of extraction efficiency, a plasma sample was eluted on
C18OH column, with isopropanolol-hexane, then was dried by
nitrogen stream and measured by the radioreceptorial method
(RRA, Nichols). Each sample was dosed in duplicate. The
recovery for this metabolite was between 60 and 80% and each
sample was corrected for its own recovery. The intra-assay
coefficient of variation was 10.0% and the interassay coefficient
was 14.0% (normal range 18 to 62 pg/ml).
Statistics were calculated utilizing a t-test for paired data,
ANOVA, simple, multiple and partial regression analysis using a
statistic package (BMDP) implemented on an Olivetti M 300-10
personal computer.
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Table 1. Basal data of renal function, calcium and phosphate parameters in patients and controls (mean SD)
Group N Age years
Creatinine clearance
mi/mm
GFR
mI/mm/i. 73 m2
i-Ca i-P
mmoi/liter
RP1
RP2
RP3
C
6
13
8
9
39.5 19.2
41.0 12.1
47.0 13.6
40.3 11.2
110.3 29
63.1 18.5
25.6 130ad
125.1 23
80
44.7 12.7a
16.1 7.5
ND
1.26 0.04
1.27 0.06
1.26 0.03
1.27 0.03
0.98 0.23
0.98 0.24
1.10 0.25
1.11 0.10
ND is not determined.
ap < 0.001, RP c
tP < 0.001, RP1 vs. RP2
CP < 0.001, RP1 vs. RP3
dp < 0.001, RP2 vs. RP3
PTH 1,25(OH)2D 25(OH)D CT
Group N pg/mi pg/mi ng/ml pg/mi
Results
Baseline determinations
11.2 47
13.9 5.9
34.1 273ag
11.5 4.8
The basal data of renal function, calcium and phosphate
parameters and calciotropic hormones in the three patient groups
and in controls are shown in Tables 1 and 2.
Both ionized calcium and inorganic phosphate serum concen-
trations were completely overlapping in the three groups of
patients and controls. Basal PTH values steadily increased with
GFR reduction (Fig. 1A). However, only two out of the 13 RP2
patients had clearly elevated PTH values (that is, above mean +2
SD of C group), while all RP3 patients presented basal PTH
concentrations above the normal range. Serum CT levels also
progressively increased with the falling of GFR values (Fig. 1B).
Again, only two RP2 patients had clearly elevated basal CT levels,
while five out of the eight RP3 patients had levels above the
normal range. Regarding 1,25(OH)2 vitamin D, its values were
linearly and directly related to GFR values (Fig. 2A). No major
difference was evident in 25(OH)vitamin D values either between
patient groups or in comparison with controls. Furthermore, no
correlation was found between its levels and GFR (Fig. 2B).
The basal values of PTH (PTHb) were inversely correlated with
1,25(OH)2 vitamin D, by a logarithmic relationship (lnPTHb =
6.47 — 0.85 ln 1,25(OH)2 vitamin D; r = 0.610, P < 0.001). A
direct linear correlation was also found between the basal levels of
PTH and CT(PTHb = 7.42 + 3.11 CT; r = O.847,P <0.0001). No
significant relationship was found between PTHb and 1,25(OH)2
vitamin D on the one hand and serum calcium and phosphate
levels on the other. However, multiple regression analysis re-
vealed that GFR levels only affected PTHb values, without any
independent role for either calcitriol or CT.
Changes in ionized calcium and PTH during Na2-EDTA infusions
Infusions of Na2-EDTA induced a progressive fall in serum
ionized calcium concentrations in all patient groups and controls
(Fig. 3A), but were without any significant difference.
Serum PTH levels, expressed as a percentage of PTH maximal
values, progressively increased during the hypocalcemic tests, and
the peak values were reached before 75th minute in each group
(Fig. 3B). However, in the RP2 and RP3 groups the increment
rate was higher than in the RP1 and C groups, with a significant
difference at 15th and 30th minutes.
Changes in serum ionized calcium and PTH during calcium
gluconate infusions
During calcium gluconate infusions, serum ionized calcium
increased progressively, without any significant difference among
RP and C groups (Fig. 4A).
Conversely, PTH (expressed as a percentage of maximal values)
decreased in a curvilinear fashion, again without any significant
difference among the studied groups (Fig. 4B), but at time 0 when
higher values were evident in the RP3 group.
Kinetic parameters of the calcium-PTH relation curve
When the results of both hypo- and hypercalcemic tests were
plotted together, the PTH changes in relation to ionized calcium
concentrations described the well-known sigmoid-shaped curve in
each group (Fig. 5).
The values of the PTH secretory parameters are shown in Table
3. PTHmx and, to a lesser extent, PTHmin steadily increased with
the reduction in GFR. Sensitivity values also, even if to a lesser
extent, progressively increased with GFR reduction. On the other
hand, setpoint values were not different in the RP groups when
compared with C.
The ratio between basal and maximal stimulated levels of PTH
also appeared to be increased in the RP3 group when compared
with the other groups.
Next we considered the interrelationships between each of the
secretory parameters and potentially affecting factors, namely,
GFR, calcitriol, CT, iCa and iP. The correlation matrix is shown
in Table 4. The PTHm was inversely related to both GFR and
calcitriol values and directly to basal CT levels. However, when a
multiple stepwise regression analysis was performed with PTHmaX
as the dependent variable and GFR, calcitriol and CT as inde-
pendent variables, GFR only appeared independently related to
PTH levels (Table 5).
Table 2. Basal hormonal parameters in patients and controls
(mean SD)
RP1 6 22.0 52de 35.2 7.2 21.3 6.1
RP2 13 39.0 13.2a 27.2 12.0 24.9 10.5
RP3 8 142.1 794ch 14.0 73Cg 19.3 11.7
C 9 26.3 12.7 39.9 9.7 23.6 9.3
ap < b p < 0.01, CP < 0.001, RP vs. C
dp < 0.01, RP1 vs. RP2
<0.01, P < 0.001, RP1 vs. RP3g<oo, "p <o.ooi, RP2vs. RP3
1716 Messa et a!: Calcium/PTH relationship cunie in CRF
Fig. 1. Correlation between basal concentrations
of PTH (A) and CT (B) and GFR values,
________________________________
corrected by BSA. Both parameters were
120 significantly related to GFR by a logarithmicV .JV ' inverse relationship (InPTH = 7.4 — 1.0
InGFR: r = 0.901, P < 0.001; InCT 5.1 —
GFR, mI/min/1.73m2 0.68 InGFR: r = 0.720, P < 0.001).
37
28
19
10
Fig. 3. A. ionized calcium levels during Na2-
EDTA inJ1sions in RP and C are depicted. The
symbols represent mean values. No difference is
evident. B. PTH values as a percentage of
maximum during the hypocalcemic test are
shown; higher values are evident at 0, 15 and
30 minutes in the RP2 and RP3 groups as
05 15 30 45 75 105 compared to both the RP1 and C (*P < 0.05;
< 0.01). Symbols are: (x) C; (S) RP1; (L)
RP2; (0) RP3.
No significant correlation was evident between PTHm,, and
both iCa and iP.
PTHmin values were also inversely correlated with GFR and
1,25(OH)2 vitamin D levels and directly with CT, with no signif-
icant correlation with iCa and iP. Again, multiple stepwise
analysis demonstrated that only GFR was independently related
to PTHmin levels (overall r = 0.712, P < 0.001; P value for GFR
0.017).
As regards sensitivity values, a weakly significant correlation
was present only with GFR values.
Regarding the setpoint, no significant correlation was found
with GFR, vitamin D and CT. On the contrary, a significant direct
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• • • Fig. 2. Correlation between GFR values,
• corrected for BSA, and 1,25(OH)2 vitamin D (A)
• and 25 (OH) vitamin D (B) concentrations. The
calcitriol levels were inversely correlated to GFR
levels, by a linear relationship [1,25(OH,12D =0 30 60 90 120 10.7 + 0.34 GFR; r 0,720, P < 0.001J. No
correlation was found between 25(OH)D and
GFR.
** **
GFR, mL/min/1.73m2
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100
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50I
II-0
05153045 75 105
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Time, minutes
relationship with iP and a closer one with iCa were evident.
Multiple stepwise analysis indicated iCa as the only independent
variable related to setpoint levels (individual P value <0.0002;
overall r = 0.741, and P < 0.0001).
The ratio between basal and maximal PTH values also ap-
peared inversely related to both GFR and 1,25(OH)2 vitamin D
levels and directly to Cf basal concentrations. In this case also,
the GFR levels were the only independently related variable when
tested by multiple regression analysis (individual P value = 0.02;
overall r = 0.632, and P < 0.01).
Finally, CT levels consistently fell after the hypocalcemic test,
from a mean value of 18.7 17, to 11.5 7.4 pg/mI (P < 0.001).
The CT reduction was not different in the three groups of patients
(RP1 5.6 4.7; RP2 4.7 3.3; RP3 8.1 6.7; P = 0.35).
Discussion
Secondary hyperparathyroidism begins very early in the course
of CRF [1—3]. In our patients, a PTH increase was evident in all
the patients with GFR values below 30 ml/min, in 2 out of 13
patients with GFR between 30 and 70 mI/mm, and in no renal
Fig. 4. Ionized calcium levels (A) and PTH
percent values (B) during calcium gluconate
0 15 30 60 90 120 infssion in RP and C. No statistically significantdifference was observed except for basal values
of PTH in the RP3 group (*P < 0.05). Symbols
are: (x) C; (•) RPI; (A) RP2; (0) RP3.
patients with GFR above 70 ml/min. The fall in GFR was
accompanied by a reduction of calcitriol and an increase in CT
levels. In our patients, the 1,25(OH)2 vitamin D levels were
inversely related to basal PTH concentrations, as found by other
authors [15]. However this correlation appeared to be completely
dependent on the common influence of GFR reduction on both
parameters, when tested by multiple regression analysis.
On the other hand, higher CT levels were found in our patients
with more pronounced GFR reduction, even though in the
absence of detectable changes in calcium concentration. This
finding does not have a clear explanation. It might be that higher
CT levels depend on retention of inactive forms of the hormone
secondary to GFR reduction. However, this hypothesis does not
seem probable because the assay we used has been proven to be
specific for the monomeric active form of CT [30, 31]. Further-
more, a marked reduction of CT concentration was evident after
the two hour hypocalcemic test without any difference in the three
groups of patients. As a second possible explanation, it cannot be
excluded that the PTh increase or some other factor connected to
GFR reduction might stimulate C-cells to produce CT. Recently,
Tomita and Millard found C-cell hyperplasia in 58% of thyroid
glands removed from uremic patients, as compared to 36% in
glands removed from patients with primary hyperparathyroidism
[32]. Whatever the cause of the CT increase, it might be hypoth-
esized that its increased serum levels contribute to skeletal
resistance to PTH action, as suggested by animal studies [33, 34]
and/or to direct PTH stimulation, as supported by in vitro studies
[35].
If increased PTH secretion is a well documented finding with
the progression of CRF, to our knowledge, no study has as yet
been performed on the secretory parameters of PTH during
stimulation and suppression tests in the pre-uremic phase of renal
insufficiency, utilizing a reliable PTH assay and utilizing both
hypo- and hypercalcemic tests. In the only study performed in
patients with moderate renal failure [1], a carboxy terminal PTH
assay was used exclusively during a hypocalcemic test, so its results
cannot be compared with ours. To our knowledge, our study is the
first in vivo assessment of the complete calcium-PTH relationship
curve in the preuremic stage of CRF.
In in vitro studies [20, 21] performed on hyperplastic parathy-
roid glands from patients with secondary hyperparathyroidism
due to chronic renal failure, increased setpoint values were found.
The other studies performed on humans on the calcium-PTH
A B
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Fig. 5. The sigmoidal relationships between semm ionized calcium and PTH
(percent of maximum) in C and RP were obtained plotting together the results
of both hypo- and hypercalcemic tests. The symbols represent mean values,
and are: (x) C; (•) RP1; (A) RP2; (0) RP3.
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Table 3. PTH secretory parameters in patient groups and controls (mean SD)
Group N
PTH PTH ...
Sensitivity
%/mmoi
.
Setpoint
mmoi/liter PTHb/PTHmpg/mi
RP1
RP2
RP3
C
6
13
8
9
80.2 18
138 25.7'
312 28.8"
87.4 28.8
12.5 7.8
16.2 12.2"
29.3 153b
8.5 3.4
659 475
628 295
894 380k'
395 150
1.23 0.04
1.24 0.04
1.24 0.03
1.24 0.04
0.28 0.07'
0.29 0.09"
0.46 0.17
0.27 0.12
ap < 005 bp < "P < 0.01, RP c
d P < 0.05, RP1 vs. RP2
ep < 0.05, fp < 0.01, RP1 vs. RP3
gp < 0.05, "P < 0.01, 'P < 0.001, RP2 vs. RP3
Table 4. Correlation matrix between the PTH secretory parameters
and potentially affecting factors [the values are r coefficient of linear
regression; (In) = logarithmic transformation]
GFR 1,25(OH)2D CT iCa iP
PTHm= —0.860
(In)"
—0.580
(ln)c
0.777" 0.063 0.141
PTHm1n —0.660
(In)"
—0.659
(In)"
0.500" 0.089 0.224
Sensitivity —0.350
(ln)a
—0.280 0.014 0.096 0.246
Setpoint —0.200 0.280 0.035 0.703" 0.434
PTHb/ —0.592 —0.390 0454b 0.212
(ln)"
0.228
PTH,,,
"P < 0.05
(ln)"
, "p < 0.01,
(In)"
"P < 0.001
relationship curve are concerned with uremic patients in dialysis
treatment [23—27] when a more advanced hyperparathyroidism is
present. In some of these studies a reduction of the setpoint values
accompanied the reduction of PTH levels after vitamin D admin-
istration. These results suggest a role of setpoint changes in
causing SHP in CRF. However, Ramirez et aI [27] questioned a
change in setpoint values in dialyzed patients with SHP.
Our data demonstrate a progressive increase in the values of
maximal and minimal PTH values, together with moderately
higher values of sensitivity in RP as compared to C, with the
declining of renal function,On the other hand, no change of
setpoint values was evident in RP groups showing higher PTH
values.
In fact, the increase of PTHm with the advance of renal failure
is the most clear finding of our study. The maximal secretory
values of PTH are a reliable index of parathyroid gland size [36].
Therefore, it is possible to argue that in our patients, with the
advance of renal failure the parathyroid gland volume steadily
increased from an early stage of CRF, The progressive increase in
PTHm was found to be affected by GFR, CT and, to a far lesser
extent, calcitriol levels. In a recent study Rodriguez, Felsenfeld
and Liach [14] first demonstrated that CT might modulate the
PTH calcemic action in renal failure in a rat model. From our
results, one could hypothesize that increased CT levels might be
related in some way to increased PTH secretion. However, it is
not possible to establish from our data whether the link between
CT and PTH secretion is a cause-effect or both hormone levels are
dependent on a common factor, which was not explored in the
present study.
The PTHmIn values were also increased with GFR reduction,
indicating that the suppressibility of the PTH gland is reduced
Table 5. Multiple stepwise regression analysis of the independent
variables GFR (Yl), CT (Y2), calcitriol (Y3) on PTHaX values (X)
Predictive
variable
Regression
coefficient Student's t test P Value
Yl —0.56 3.54 0.0019
Y2 0.27 1.97 0.0621
Y3 —0.07 0.48 0.6382
r 0.883; F 24.71; P < 0.0001
with ongoing CRF. Furthermore, the ratio between basal and
maximal P11-I also increases with the reduction of GFR, indicat-
ing that the increased tonic basal secretion is accompanied by a
decrease in secretory reserve.
The sensitivity and setpoint results deserve additional method-
ological consideration. Some in vitro [20, 21] and in vivo studies
[24] obtained the above values from an inhibition test only, by
increasing calcium concentration. The information given by this
kind of calculation is quite different from that obtained by the
complete calcium-PTH relation curve, which is obtained by
performing both hypo- and hypercalcemic challenges (as in our
study). The former defines the setpoint value as the calcium level
necessary to have a half-reduction of PTH basal levels, and the
latter as the calcium level needed to obtain the half-maximal
stimulation of parathyroid gland secretion. It is easy to argue that
the first method gives a higher setpoint and, possibly, lower
sensitivity values than the second. Furthermore, the results ob-
tained by the first methodology are often not related to the real
parameters of the complete sigmoidal curve. Secondly, the hypo-
and hypercalcemic tests must be separated by a time sufficient
enough to allow the calcium concentration to return to basal
levels before the subsequent test; this is necessary to obviate
artifactuarial assessment of secretory parameters, owing to the
"hysteresis" phenomenon [22, 23] which consists of a lower or
higher PTH concentration for a given calcium level during
recovery respectively from hypo- or hypercalcemia. In our study,
calcium concentrations before the second test always returned to
basal levels. Finally, the computation methodology of secretory
parameters might introduce some further difficulties in comparing
the results from different studies, as pointed out by Fensenfeld
and Llach [221. The methodology of computation of setpoint
values we used was quite close to the original mathematical model
suggested by Rodbard and Hutt, as demonstrated by the close
relationship between the setpoint values calculated by our method
and those obtained by logit/log transformation.
The sensitivity values we found were slightly, but significantly,
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increased in all RP groups, even in the RP1 patients where no
detectable change in PTH levels was evident. However, no
relationship was found between sensitivity and potential causal
factors of SHP, excluding GFR values. Since sensitivity is ex-
pressed as a percentage change in Pm, this parameter should
reflect PTH production per unitary volume of the parathyroid
glands. This finding, together with the steady increase of PTH
maximal levels, suggests that from the early reduction of the GFR
an increased secretion rate per parathyroid cell and a progressive
increase in glandular mass are the first initiating events in the
beginning and development of SHP; this is without any apparent
link with known causative factors, but exclusively depends on
GFR reduction.
A further clear finding of our study was that no real change of
setpoint values was evident with the progression of CRF and the
early development of SHP. This finding is in contrast with the
hypothesis of a causative role of setpoint change in the pathogen-
esis of SHP.
Indeed, from our data we cannot argue for a setpoint modifi-
cation as a primary event in the pathogenesis of SHP in CRF.
However, it cannot be excluded that in more advanced phases of
SHP, in the course of CRF the setpoint might change, justifying
changes in the serum calcium concentration.
In conclusion, our study demonstrates that: (1) SHP begins
early with the progression of CRF; (2) the increase of PTH
secretion, at least in this stage of CRF, is mainly characterized by
increased secretion capacity without any change of setpoint, and
this finding is consistent with an early hyperplastic change, but not
with derangement in calcium concentration control by parathy-
roid glands; and (3) in addition to the already known factors,
increased calcitonin levels seem to be, in an as yet not clear way,
related to PTH hypersecretion.
Reprint requests to Piergiorvjo Messa, M.D., Nephrology, City Hospital,
33100 Udine, Italy.
Appendix
According to Rodbard and Hutt [29], a sigmoidal curve is described by
the following four parameter logistic function:
A-D
=
1 + C) + D
where Y is a generic response variable, A is the upper asymptote, D the
lower asymptote, X the value of independent variable expressed in log
scale, C is the mid-range value; f3 is the slope of the following linear
regression:
where
and
Y' a + 13X'
= logit (F)
logit (F) = In (Y/[1 — Y])
Y= (Y-D)/(A-D)
X'' ln(X)
If Y, X, A and D values are known, the C term, which represents the X'
value corresponding to Y' = 0, is easily obtained by equation (2):
lnC =
Utilizing the above formulas for calculation of the setpoint value of the
PTH secretion curve, one can utilize the following identities:
Y = PTH values, expressed as a fraction of PTHm
X = ionized calcium concentration
A = PTHmX, for definition equal to unityD = PTHmi, as fraction of PTHmC = Setpoint value, that is, ionized calcium concentration corre-
sponding to the mid-range value of PTH.
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